• Self-Assembling Virus-Mimicking Particles for Extrahepatic m

  2026-05-13

  This reference study introduces a bottom-up engineered, self-assembling enveloped virus-mimicking particle (EVMP) platform that enables targeted and efficient mRNA delivery to extrahepatic organs, notably the lung and spleen. Leveraging rational peptide design and phospholipid envelope tuning, the platform addresses limitations in current delivery systems, with implications for advancing mRNA therapeutics beyond hepatic applications.

• BODIPY 581/591 C11: Ratiometric Probe for Lipid Peroxidation

  2026-05-12

  BODIPY 581/591 C11 enables precise, live-cell lipid peroxidation detection with ratiometric quantification, empowering oxidative stress research in complex disease models. Its spectral shift, photostability, and specificity deliver unmatched sensitivity for evaluating antioxidant interventions and dissecting redox-regulated cell fate decisions.

• ER Stress-Induced Prometastatic States in Tumor Cell Surviva

  2026-05-12

  This study uncovers how tumor cells surviving near-death experiences adopt stable, prometastatic phenotypes, driven by ER stress, reprogramming, and cytokine signaling. These findings reshape our understanding of metastasis origins and highlight experimental approaches—such as the use of anion transport inhibitors like DIDS—to dissect these cellular transitions.

• Valemetostat (DS-3201): Precision EZH2 Inhibition for Lympho

  2026-05-11

  Valemetostat (DS-3201) delivers targeted, dual EZH1/EZH2 inhibition for advanced epigenetic cancer therapy research. Its nanomolar potency and high selectivity empower robust, reproducible experimental workflows, especially in relapsed/refractory follicular lymphoma and EZH2-mutant settings.

• Tioconazole: Assay Rigor and Mechanistic Precision in Antifu

  2026-05-11

  Explore the multifaceted role of Tioconazole as an antifungal medication in research, with a focus on mechanistic depth, assay rigor, and translational considerations. This article uniquely connects metabolic-genomic insights to practical antifungal drug development.

• EdU Flow Cytometry Assay Kits (Cy3): Precision DNA Synthesis

  2026-05-10

  The EdU Flow Cytometry Assay Kits (Cy3) offer a robust, non-denaturing approach for quantifying cell proliferation via S-phase DNA synthesis measurement. Leveraging copper-catalyzed azide-alkyne cycloaddition (CuAAC), these kits deliver superior sensitivity and compatibility compared to traditional BrdU assays. This article details mechanisms, benchmarks, and workflow integration for advanced cell cycle analysis by flow cytometry.

• Sunitinib: Multi-Targeted RTK Inhibitor for RCC Research Wor

  2026-05-09

  Sunitinib empowers cancer researchers with precision RTK pathway inhibition and apoptosis induction, especially in renal cell carcinoma (RCC) and nasopharyngeal carcinoma models. This article decodes recent advances—including combination strategies to overcome resistance—and delivers actionable, stepwise protocols with troubleshooting tips for robust experimental outcomes.

• HO-1-Mediated ROS Modulation Disrupts HBV Replication Pathwa

  2026-05-08

  This study reveals that isochlorogenic acid A impairs hepatitis B virus (HBV) replication by upregulating heme oxygenase-1 (HO-1) and altering intracellular reactive oxygen species (ROS) levels. The findings underscore HO-1 as a multifaceted regulator of HBV morphogenesis and suggest new experimental routes for targeting viral persistence.

• Dual “Engage & Evasion” Strategy Boosts EV Therapy Efficacy

  2026-05-08

  Liu et al. introduce a two-step 'Engage & Evasion' approach to overcome rapid mononuclear phagocyte system (MPS) clearance of extracellular vesicles (EVs), enhancing their systemic retention and therapeutic impact in ischemic disease models. This strategy leverages sequential MPS saturation and CD47-enriched EV delivery, offering a promising advance for targeted regenerative therapies.

• ONX-0914 (PR-957): Redefining Immunoproteasome Inhibition

  2026-05-07

  This thought-leadership article explores how ONX-0914 (PR-957) advances selective immunoproteasome inhibition, offering mechanistic insight, protocol guidance, and strategic recommendations for translational researchers. Drawing from recent breast cancer proteasome heterogeneity findings and APExBIO’s robust product data, it connects molecular rationale with practical workflow and clinical impact.

• Cyclopamine (SKU A8340): Reliable Hedgehog Inhibition in Can

  2026-05-07

  This article provides a scenario-driven, evidence-based exploration of Cyclopamine (SKU A8340) as a Hedgehog signaling inhibitor for cancer and developmental biology research. Real-world lab challenges are addressed with practical solutions, protocol optimization, and vendor selection insights, all grounded in peer-reviewed data and APExBIO’s product reliability.

• Z-YVAD-FMK: Precision Caspase-1 Inhibitor for Pyroptosis Ass

  2026-05-06

  Z-YVAD-FMK empowers researchers to dissect caspase-1–mediated cell death with exceptional selectivity and workflow flexibility. Its irreversible inhibition profile, high cell permeability, and robust performance in apoptosis and inflammasome studies set the stage for advanced experimental design and troubleshooting.

• Angiotensin III: Advanced Applications in RAAS Research

  2026-05-06

  Angiotensin III (human, mouse) empowers high-fidelity modeling of RAAS-mediated cardiovascular and neuroendocrine pathways, with peer-reviewed evidence linking its activity to both classical and emerging disease contexts. This guide translates recent mechanistic insights and workflow best practices into actionable protocols—optimizing the impact of APExBIO’s validated peptide in complex experimental systems.

• Pharmacokinetic Variability of CSBTA Alkaloids in MASH: Insi

  2026-05-05

  This study systematically characterizes the pharmacokinetics and tissue distribution of Corydalis saxicola Bunting total alkaloids (CSBTA) in mouse models of metabolic dysfunction-associated steatohepatitis (MASH) induced by a high-fat, high-cholesterol diet. The research highlights how pathological changes alter drug metabolizing enzymes and transporters, informing dosing strategies for MASLD/MASH therapies.

• Genistein in Mechanotransduction: Bridging Tyrosine Kinase I

  2026-05-05

  Explore how Genistein, a selective tyrosine kinase inhibitor, advances cancer chemoprevention by modulating cytoskeleton-dependent autophagy. This in-depth analysis reveals unique mechanistic insights and protocol guidance not found in standard workflows.

15841 records 1/1057 page Next 12345 下5页 Last page